Hi [[ session.user.profile.firstName ]]

pharmaphorum

  • Date
  • Rating
  • Views
  • The future of the clinical trial – collaboration and patient centricity
    The future of the clinical trial – collaboration and patient centricity Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie Recorded: May 3 2017 73 mins
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Life sciences promotional content management for speed, compliance and insight
    Life sciences promotional content management for speed, compliance and insight David Bennett, Andrew McConaghie Recorded: Apr 27 2017 69 mins
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • When small becomes big: orphan medicines, advances, access and affordability
    When small becomes big: orphan medicines, advances, access and affordability Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah Recorded: Apr 10 2017 75 mins
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
  • Unlocking the value of pharmacists to reach the right patients and consumers
    Unlocking the value of pharmacists to reach the right patients and consumers Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie Recorded: Mar 29 2017 70 mins
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • Approval and access: Overcoming the final hurdle of drug development
    Approval and access: Overcoming the final hurdle of drug development Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium Recorded: Mar 10 2017 61 mins
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
  • Taking health wearables to the next level – where is the market heading?
    Taking health wearables to the next level – where is the market heading? Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie Recorded: Dec 8 2016 63 mins
    With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
    In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
    – The user perspective: perception, adoption and expectations today and tomorrow
    – The technology perspective: biggest successes and most room for improvements
    – The societal and regulatory perspective: cost and risks versus benefits and opportunities
  • The Patient Centric Launch – business insights key to success in Europe
    The Patient Centric Launch – business insights key to success in Europe Nina Felton, Nick Cooper Larry R Smith II and Andrew McConaghie (moderator) Recorded: Nov 30 2016 61 mins
    Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces.
    Key topics to be discussed include:
    – The challenges of launching a product in Europe
    – How pharma can improve its understanding of the process through the use of business intelligence
    – How insights from new data can be applied to the process of launch excellence
    – The role of real-world data in launch strategy
    – The downstream effect of applying real-world data to product launch on patient outcomes.
  • The hepatitis C conundrum: balancing cost and affordability
    The hepatitis C conundrum: balancing cost and affordability Ashley Pitcher, Natasha Martin, Paul Tunnah Recorded: Nov 22 2016 68 mins
    Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.

    Key topics to be discussed include:
    – The burden of HCV
    – The current market landscape
    – The current patient access model and its impact on budget
    – Cost efficiencies shown by modelling
    – Cure versus lifetime treatment costs
  • Demand Assessment Research: adopting insights from behavioural economics
    Demand Assessment Research: adopting insights from behavioural economics Duncan Munro and Andrew McConaghie Recorded: Nov 16 2016 52 mins
    Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
    This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
    The masterclass will:
    •Introduce demand assessment research and why it is important to healthcare market research
    •Discuss how insights from behavioural economics can improve quantitative demand assessment market research
    •Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.

Embed in website or blog